Nivolumab in NSCLC: latest evidence and clinical potential
Raghav Sundar ; Byoung-Chul Cho ; Ross A. Soo ; Julie R. Brahmer
Therapeutic Advances in Medical Oncology, Vol.7(2) : 85~96, 2015
Therapeutic Advances in Medical Oncology
New insight on the interaction between the immune system and tumor has identified the programmed death-1/programmed death-1 ligand pathway to be a key player in evading host immune response. The immune checkpoint modulator, nivolumab (BMS-936558/ONO-4538), is the first PD-1 inhibitor to gain regulatory approval, for the treatment of patients with unresectable melanoma. This review will discuss results from early phase studies of nivolumab in solid tumors including non-small cell lung cancer (NSCLC) as well as studies of nivolumab in combination with chemotherapy, other immune modulators and molecular targeted therapy in patients with NSCLC.